Related Experiment Video
Updated: Aug 14, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
Vikash Kansal1,2, Andre J Burnham1,2, Brendan L C Kinney1,2
1Department of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USA.
Background:
Anti-PD-1 immune checkpoint blockade is approved for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but few patients respond. Statin drugs (HMG-CoA reductase inhibitors) are associated with superior survival in several cancer types, including HNSCC. Emerging data suggest that manipulation of cholesterol may enhance some aspects of antitumor immunity.
Methods:
We used syngeneic murine models (mouse oral cancer, MOC1 and TC-1) to investigate our hypothesis that a subset of statin drugs would enhance antitumor immunity and delay tumor growth.
Results:
Using an ex vivo coculture assay of murine cancer cells and tumor infiltrating lymphocytes, we discovered that all seven statin drugs inhibited tumor cell proliferation. Simvastatin and lovastatin also enhanced T-cell killing of tumor cells. In mice, daily oral simvastatin or lovastatin enhanced tumor control and extended survival when combined with PD-1 blockade, with rejection of MOC1 tumors in 30% of mice treated with lovastatin plus anti-PD-1. Results from flow cytometry of tumors and tumor-draining lymph nodes suggested T cell activation and shifts from M2 to M1 macrophage predominance as potential mechanisms of combination therapy.
Conclusions:
These results suggest that statins deserve further study as well-tolerated, inexpensive drugs that may enhance responses to PD-1 checkpoint blockade and other immunotherapies for HNSCC.
Insights
Statins enhance anti-PD-1 immunotherapy for head and neck squamous cell carcinoma (HNSCC) by boosting antitumor immunity. This combination therapy shows promise in delaying tumor growth and improving survival in preclinical models.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Anti-PD-1 immune checkpoint blockade is a first-line HNSCC treatment with limited response rates.
- Statin drugs are linked to better survival in various cancers, including HNSCC.
- Cholesterol modulation may improve anti-tumor immune responses.
Purpose of the Study:
- To investigate if statins enhance anti-tumor immunity and slow tumor growth in HNSCC.
- To test the hypothesis that statins augment immunotherapy efficacy.
Main Methods:
- Utilized syngeneic murine models (MOC1 and TC-1) for oral cancer.
- Conducted ex vivo co-culture assays with murine cancer cells and tumor-infiltrating lymphocytes.
- Administered oral simvastatin or lovastatin in combination with PD-1 blockade to mice.
Main Results:
- All seven statins tested inhibited tumor cell proliferation in vitro.
- Simvastatin and lovastatin enhanced T-cell mediated tumor cell killing.
- Combination therapy with statins (simvastatin or lovastatin) and anti-PD-1 improved tumor control and survival in mice.
- Complete tumor rejection was observed in 30% of mice treated with lovastatin plus anti-PD-1.
- Flow cytometry indicated increased T-cell activation and a shift towards M1 macrophages.
Conclusions:
- Statins show potential as well-tolerated, cost-effective agents to improve immunotherapy outcomes in HNSCC.
- Further research into statins as adjuncts to PD-1 blockade and other immunotherapies is warranted.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...